VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE AMEX: CVM) announced today that the Department of Health, Taiwan has issued an approval letter that allows enrollment of patients to begin in Taiwan in the Phase III clinical trial of Multikine®. The approval letter was issued by the Department of Health after manufacturing and stability data for the batches of Multikine that will be used in the trial in Taiwan were provided to them. The study in Taiwan is being run and paid for by CEL-SCI’s partner, Orient Europharma. Seven clinical centers will be enrolling patients. Enrollment of patients is expected to start within the next month in Taiwan.
